RESUMEN
BACKGROUND/AIM: Over the past several decades, new anti-cancer drugs have been developed for the treatment of epithelial ovarian cancer. The development of drugs has led to changes in improving the prognosis of ovarian cancer patients. One of these drugs, bevacizumab, is used for advanced or recurrent ovarian cancer. In this study, we aimed to evaluate survival improvement in patients with platinum-resistant relapsed epithelial ovarian cancer (PR-ROC) after introduction of bevacizumab in real world experience. PATIENTS AND METHODS: We retrospectively divided patients with PR-ROC into two groups: bevacizumab plus chemotherapy (BEV-CT group) and chemotherapy alone (CT group). Progression-free survival (PFS), the primary endpoint, between two groups was compared to evaluate whether survival outcomes were improved. In addition, overall survival (OS) was also compared. RESULTS: A total of 154 patients were included in the study: 57 and 97 patients in the BEV-CT and CT groups, respectively. OS was significantly longer in the BEV-CT group than in the CT group. The use of bevacizumab was identified as a favorable prognostic factor for OS. In a subgroup analysis confined to second-line chemotherapy, PFS and OS were statistically different between groups. More patients in the CT group suffered hematologic adverse events of grade 3 or above than patients in the BEV-CT group. CONCLUSION: In a real-world clinical setting, introduction of bevacizumab led to improvement of OS in patients with PR-ROC with a tolerable toxicity.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Bevacizumab , Resistencia a Antineoplásicos , Recurrencia Local de Neoplasia , Neoplasias Ováricas , Humanos , Bevacizumab/uso terapéutico , Bevacizumab/administración & dosificación , Bevacizumab/efectos adversos , Femenino , Persona de Mediana Edad , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/mortalidad , Neoplasias Ováricas/patología , Anciano , Recurrencia Local de Neoplasia/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Adulto , Resultado del Tratamiento , Pronóstico , Estudios Retrospectivos , Carcinoma Epitelial de Ovario/tratamiento farmacológico , Carcinoma Epitelial de Ovario/mortalidad , Platino (Metal)/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico , Antineoplásicos Inmunológicos/efectos adversos , Antineoplásicos Inmunológicos/administración & dosificaciónRESUMEN
OBJECTIVE: The purpose of our study was to determine objective histogram parameters on elastography that could predict poor prognosis factors of conventional papillary thyroid microcarcinomas (PTMCs). METHODS: From September to November in 2012, 79 patients with a diagnosis of PTMCs were included. Mean values of clinicopathologic variables and histogram parameters on elastography were compared between groups with or without poor prognostic factors using the Student t test, χ test, or Fisher exact test. Multivariate logistic regression analysis adjusted for age, gender, and size was performed to investigate independent elastography parameters predicting extrathyroidal extension, lymph node metastasis, and high TNM stage (III-IV). RESULTS: Of 79 patients with PTMCs, 32 (40.5%) had extrathyroidal extension, 14 (17.7%) had lymph node metastasis, and 18 (22.8%) received a diagnosis with a high TNM stage. None of the histogram parameters on elastography had significant associations with any of the poor prognostic factors. CONCLUSIONS: There were no significant associations between all histogram parameters on elastography and known poor prognostic factors such as extrathyroidal extension, lymph node metastasis, and high TNM stage in patients with PTMCs.